Drug use · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Drug prices · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Drug expenditure · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Treatment outcomes (Different measures) · CALD patients and their health professionals (Primary care settings in high income countries)
1 finding from 1 review
Intervention not reported
Health behaviours · CALD patients and their health professionals (Primary care settings in high income countries)
1 finding from 1 review
Intervention not reported
Involvement in care (Mutual understanding) · CALD patients and their health professionals (Primary care settings in high income countries)
1 finding from 1 review
Intervention not reported
Evaluations of care (Different measures) · CALD patients and their health professionals (Primary care settings in high income countries)
1 finding from 1 review
Intervention not reported
Health professionals knowledge & understanding (Awareness of racial differences) · CALD patients and their health professionals (Primary care settings in high income countries)
1 finding from 1 review
Intervention not reported
Adverse events · CALD patients and their health professionals (Primary care settings in high income countries)
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Complete resection ‐ iMRI · high‐grade glioma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower hospitalisation for RSV infection compared with placebo (high certainty).
1 finding from 1 review
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in admission to ICU compared with motavizumab (moderate certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to higher mechanical ventilation for RSV infection compared with motavizumab (high certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in supplemental oxygen therapy for RSV infection compared with motavizumab (moderate certainty).
1 finding from 1 review
Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in number of children reporting any SAE compared with motavizumab (high certainty).
1 finding from 1 review
All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower admission to ICU compared with placebo (high certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
It is very uncertain whether palivizumab changes mechanical ventilation for RSV infection compared with placebo (very low certainty).
1 finding from 1 review